We are proud to announce a major milestone in the growth of MyCural Therapeutics — the formation of a new, strategically focused board of directors. This exceptional group of leaders brings deep industry experience, diverse expertise, and a shared passion for transforming cancer therapy. Their guidance will be instrumental as we shape our long-term strategy, accelerate company growth, and attract key investors for future funding rounds.
Meet the members of our new board:
-
Ann-Charlotte Rosendahl – Chair of the Board
With more than 20 years of international experience in senior roles within the pharmaceutical industry, Ann-Charlotte most recently served as Head of Global Launch Strategy at Roche. Her strategic vision and leadership in global commercialization are invaluable assets as we prepare to scale.
-
Gunilla Ekström
Former Global Product Director at AstraZeneca and co-founder of Gesynta Pharma, a therapeutics company that recently secured €27 million in funding. Gunilla brings deep operational knowledge and hands-on experience in successful biotech scaling.
-
Klas Wiman, MD, PhD
A renowned Professor at Karolinska Institutet, cancer biologist, and co-founder of Aprea Therapeutics, which was successfully listed on Nasdaq in 2019. Klas offers unmatched scientific insight and a proven track record in oncology drug discovery.
-
Pernilla Sandwall
With over 20 years in clinical operations at MSD and 15 years in Swedish Life Science SMEs, Pernilla has held leadership roles at three publicly listed companies. She brings a strong background in clinical development and has successfully driven funding rounds both as a CEO and board member.
A Strategic Step Forward
This newly formed board marks an exciting new chapter for MyCural. With their collective experience in biotech, drug development, clinical operations, and investor relations, we are poised to take bold steps toward achieving our mission: to revolutionize cancer care through innovative, MYC-targeted therapies.
We’re entering this next phase with optimism, ambition, and confidence—knowing we have the right leadership in place to navigate the path ahead.
Stay tuned for what’s next as we continue our journey toward groundbreaking progress in cancer therapy. The future starts now.
